Cycle, Medherant partner to develop patch drug delivery
Cycle Pharmaceuticals and Medherant have inked a deal to develop and commercialize multiple medicines using Medherant's Tepi Patch transdermal delivery technology.
Adare acquires Orbis for drug discovery
Adare Pharmaceuticals on April 30 acquired pharmaceutical technology firm Orbis Biosciences. Financial details were not disclosed. The acquisition will enhance Adare's ability to manufacture products for the global pharmaceutical, animal health, and over-the-counter markets.
AbCellera secures COVID-19 drug development funding
AbCellera Biologics has secured $175.6 million Canadian ($124.7 million U.S.) from the Canadian government's Innovation, Science, and Economic Development Strategic Innovation Fund to advance its efforts to discover antibodies for use in antiviral COVID-19 drugs.
U.K. schools get $3.8M to build COVID-19 vaccine, more
Citadel and Citadel Securities gifted 3 million pounds (about $3.8 million U.S.) to medical universities to accelerate COVID-19 research and vaccine development.
AMRI ups hydroxychloroquine sulfate API production
AMRI Global will boost production of hydroxychloroquine sulfate active pharmaceutical ingredients (API) due to its potential effectiveness in treating COVID-19 symptoms in patients.
Inovio expands manufacturing for COVID-19 vaccine
Inovio has partnered with German contract manufacturer Richter-Helm BioLogics to produce large-scale quantities of Inovio's investigational DNA vaccine.
COVID-19: A double-edged sword for the pharma industry
The COVID-19 pandemic is causing major disruptions to pharmaceutical R&D activities, despite the pressing need for treatments and diagnostics for the novel coronavirus. In a new article, Ivan Gandayuwana of Strategic Directions International examines the multiple impacts COVID-19 is having on pharma.  Discuss
Valo to develop pan-coronavirus vaccine
Valo Therapeutics announced that it is working on the development of a potential COVID-19 vaccine with applications across future pandemics.
Experts discuss promising strategies for tackling SARS-CoV-2
What's the best strategy for developing treatments for the SARS-CoV-2 virus? The most promising approaches for a rapid response are antivirals and gene therapy, according to a new review article published April 24 in Frontiers in Microbiology.  Discuss
J&J announces manufacturing collaboration for COVID-19 vaccine
Johnson & Johnson, a Janssen Pharmaceuticals company, announced on April 24 a collaboration with Emergent BioSolutions to support the manufacturing of its lead investigational COVID-19 vaccine candidate.
Science Advisory Board on LinkedIn
Science Advisory Board on Facebook
Science Advisory Board on Twitter